Beam Therapeutics:经BEAM-302 60毫克治疗后,校正型M-AAT占总AAT的94%,同时突变型Z-AAT降低84%

美股速递
Yesterday

在Beam Therapeutics公司BEAM-302 60毫克治疗方案下,研究数据显示校正型M-AAT占全部AAT的比例高达94%。与此同时,突变型Z-AAT水平出现显著下降,降幅达到84%。这一结果凸显了该疗法在精准编辑方面的潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10